Figures & data
Figure 1 Patients remaining on subcutaneous IFN β-1a treatment over time.
![Figure 1 Patients remaining on subcutaneous IFN β-1a treatment over time.](/cms/asset/e22a4def-2d78-45f2-bdb8-1ec5867cd9bf/dppa_a_59496_f0001_b.jpg)
Table 1 Odds of patients with MS remaining on subcutaneous IFN β-1a treatment up to Month 24 when receiving MySupport versus NHS support only
Register now or learn more
Open access
Figure 1 Patients remaining on subcutaneous IFN β-1a treatment over time.
Table 1 Odds of patients with MS remaining on subcutaneous IFN β-1a treatment up to Month 24 when receiving MySupport versus NHS support only
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.